Webcast: IBD

To begin, click button below:

Release Date: February 17, 2009
Expiration Date: February 17, 2010

Sponsorship Statement
This activity is sponsored by Imedex^®, LLC.

Accreditation Statement
ACCME

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 11 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

Target Audience
This activity is intended for gastroenterologists, endocrinologists, surgeons, internists, clinical researchers and other persons in the healthcare community with an interest in the treatment and management of patients with inflammatory bowel disease.

Overview
The content of this Webcast includes every aspect of the care of patients with ulcerative colitis and Crohn’s Disease from the management of psychological and sociological considerations to surgical management, new and emerging biologic therapies, research and clinical trial data. A phenomenal faculty composed of national and international experts in inflammatory bowel disease (IBD) pour out their respective knowledge and perspectives related to management of this impressive group of disorders.

Objectives
After completing this activity, the participant will be able to:

Review significant advances in therapeutic options particularly biologics and immunomodulators in the treatment of IBD
Discuss emerging genomic research developments as related to the pathophysiology of IBD
Understand evolving patient management and treatment strategies for intestinal and extraintestinal complications in IBD
Review immunological and microbial aspects relevant to the pathology of IBD
Describe appropriate strategy options for the management of pediatric and adolescent patients with IBD
Recommend disease management options based on current understanding of case presentations from national IBD thought leaders
Discuss advantages and disadvantages of current pharmacological therapies for IBD
Identify the most appropriate and effective surgical techniques in the treatment of IBD
Review clinical challenges encountered by clinicians including the simple dichotomy between ulcerative colitis and Crohn’s disease toward enhancement of overall patient outcomes

Support
This activity is supported by Imedex, LLC and the Crohn’s and Colitis Foundation of America.

Disclosure Statement
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Russell D. Cohen, MD	AstraZeneca Pharmaceuticals LP³; ISIS Pharmaceuticals, Inc.²; Johnson & Johnson⁴; NPS Pharmaceuticals, Inc.²; PDL BioPharma, Inc.²; StoneBridge Pharma, LLC²; Tanabe Seiyaku CO., LTD³
Peter Higgins, MD, PhD	Genentech BioOncology²; Novartis Pharmaceuticals Corporation⁵; Otsuka American Pharmaceuticals, Inc.⁵
Asher A. Kornbluth, MD	Bristol-Myers Squibb Company¹; Given Imaging Ltd²; Osiris Therapeutics, Inc.¹
Gary R. Lichtenstein, MD	AstraZeneca Pharmaceuticals LP¹; Bristol-Myers Squibb Company^1,2; Schering-Plough Corporation^2,3
Edward V. Loftus, Jr., MD	PDL BioPharma, Inc.¹; Schering-Plough Corporation¹
Darrell S. Pardi, MD	AstraZeneca Pharmaceuticals LP¹
Daniel H. Present, MD	Mayo Clinic¹; National Institute of Health¹; Teva Pharmaceutical Industries, Ltd.¹
William J. Sandborn, MD	ActogeniX²; Atlantic Healthcare Limited²; Bayer HealthCare Corporation²; Bristol-Myers Squibb Company^1,2; Novartis Pharmaceuticals Corporation¹; PDL BioPharma, Inc.^1,2; Pfizer Inc^1,2
Bruce E. Sands, MD	Alba Therapeutics Corporation^2,5; Biogen Idec Inc.²; Bristol-Myers Squibb Company^1,2,5; Cerimon Pharmaceuticals, Inc.^1,2,5; Foundation for Clinical Research in IBD⁵; Novartis Pharmaceuticals Corporation¹; Otsuka American Pharmaceuticals, Inc.^2,3
David A. Schwartz, MD	Cellerix, S. A.²
Bo Shen, MD	Ocera Therapeutics Inc¹
William J. Tremaine, MD	NPS Pharmaceuticals, Inc.²

The following speakers have reported an affiliation with the supporters of this activity:

David G. Binion, MD	Abbott Laboratories^2,3; Centocor, Inc.^1,2,3; Elan Biogen^1,2,3; Salix Pharmaceuticals, Inc.²; UCB, Inc.^2,3
Russell D. Cohen, MD	Abbott Laboratories^2,3; Alaven Pharmaceutical LLC²; Axcan Pharma Inc.^2,3; Elan Pharmaceuticals, Inc.²; Proctor & Gamble Pharmaceuticals, Inc.³; Prometheus Laboratories Inc.³; Salix Pharmaceuticals, Inc.^2,3; Shire Pharmaceuticals Limited^2,3; UCB, Inc.^2,3
Stephen B. Hanauer, MD	Abbott Laboratories^1,2; Centocor, Inc.^{^1,2,3}; Prometheus Laboratories Inc.^1,2,3; UCB, Inc.^1,2,3
Sunanda V. Kane, MD	Abbott Laboratories²; Centocor, Inc.²; Elan Pharmaceuticals, Inc.^1,2; Proctor & Gamble Pharmaceuticals, Inc.^2,3; Shire Pharmaceuticals Limited¹; UCB, Inc.¹
Asher A. Kornbluth, MD	Abbott Laboratories^1,3; Centocor, Inc.^1,2; Elan Pharmaceuticals, Inc.^2,3; Proctor & Gamble Pharmaceuticals, Inc.^1,2,3; Prometheus Laboratories Inc.^2,3; Salix Pharmaceuticals, Inc.^1,2,3; Shire Pharmaceuticals Limited^2,3
Bret A. Lashner, MD	Abbott Laboratories⁵; Elan Pharmaceuticals, Inc.⁵; Millennium Pharmaceuticals, Inc.⁵; Proctor & Gamble Pharmaceuticals, Inc.⁵; Prometheus Laboratories Inc.⁵; Shire Pharmaceuticals Limited⁵; UCB, Inc.⁵
Gary R. Lichtenstein, MD	Abbott Laboratories^1,2; Centocor, Inc.^1,2,3; Elan Pharmaceuticals, Inc.²; Millennium Pharmaceuticals, Inc.¹; Proctor & Gamble Pharmaceuticals, Inc.^1,2,3; Prometheus Laboratories Inc.^1,2; Salix Pharmaceuticals, Inc.^1,2,3; Shire Pharmaceuticals Limited^1,2,3; UCB, Inc.^1,2
Edward V. Loftus, Jr., MD	Abbott Laboratories^1,2; Elan Pharmaceuticals, Inc.²; Proctor & Gamble Pharmaceuticals, Inc.²; Salix Pharmaceuticals, Inc.²; Shire Pharmaceuticals Limited²; UCB, Inc.²
Richard P. MacDermott, MD	Abbott Laboratories³; Centocor, Inc.³; Proctor & Gamble Pharmaceuticals, Inc.³ Salix Pharmaceuticals, Inc.³; Shire³; UCB, Inc.³
Uma Mahadevan, MD	Abbott Laboratories²; Centocor, Inc.²; Elan Pharmaceuticals, Inc.²; Proctor & Gamble Pharmaceuticals, Inc.²
Darrell S. Pardi, MD	Proctor & Gamble Pharmaceuticals, Inc.¹; Salix Pharmaceuticals, Inc.^1,2
Daniel H. Present, MD	Abbott Laboratories^1,2; Alaven Pharmaceutical LLC^1,2; Axcan Pharma Inc.^2,3; Crohn’s & Colitis Foundation of America (CCFA)¹, Centocor, Inc.^1,2; Elan Pharmaceuticals, Inc.^1,3,4; Proctor & Gamble Pharmaceuticals, Inc.^1,2,3 Salix Pharmaceuticals, Inc.³; Shire Pharmaceuticals Limited³; UCB, Inc.^1,2,3
Miguel Regueiro, MD	Abbott Laboratories^2,5; Axcan Pharma Inc.^2,3,5; Centocor, Inc.^1,2,3,5; Proctor & Gamble Pharmaceuticals, Inc.^2,3,5; Prometheus Laboratories Inc.^3,5; Shire Pharmaceuticals Limited⁵; UCB, Inc.^2,5
David T. Rubin, MD	Abbott Laboratories²; Axcan Pharma Inc.²; Proctor & Gamble Pharmaceuticals, Inc.^1,2; Prometheus Laboratories Inc.^1,2; Salix Pharmaceuticals, Inc.^1,2; Shire Pharmaceuticals Limited²; UCB, Inc.^,3
William J. Sandborn, MD	Abbott Laboratories^1,2; Centocor, Inc.^1,2; Millennium Pharmaceuticals, Inc.²
Bruce E. Sands, MD	Abbott Laboratories^1,2,5; CCFA⁵; Centocor^1,2,3,5; Elan Pharmaceuticals, Inc.^1,2,5; Millennium Pharmaceuticals, Inc.^2,5, Proctor & Gamble Pharmaceuticals, Inc.^1,2,3,5; UCB, Inc.^2,3,5
David A. Schwartz, MD	Abbott Laboratories^1,2,3; Axcan Pharma Inc.²; Centocor, Inc.³; Proctor & Gamble Pharmaceuticals, Inc.^1,3; Prometheus Laboratories Inc.³; Salix Pharmaceuticals, Inc.³; Shire Pharmaceuticals Limited³
Joseph H. Sellin, MD	Abbott Laboratories³; Centocor, Inc.^2,3; Elan Pharmaceuticals, Inc.²; Proctor & Gamble Pharmaceuticals, Inc.²; Prometheus Laboratories Inc.³
Bo Shen, MD	Abbott Laboratories¹; Salix Pharmaceuticals, Inc.¹; UCB, Inc.³
Corey A. Siegel, MD	Abbott Laboratories^2,3; Elan Pharmaceuticals, Inc.²; Proctor & Gamble Pharmaceuticals, Inc.^2,3; UCB, Inc.^2,3
William J. Tremaine, MD	Proctor & Gamble Pharmaceuticals, Inc.¹
Fernando S. Velayos, MD, MPH	Centocor, Inc.¹; Proctor & Gamble Pharmaceuticals, Inc.¹; Shire Pharmaceuticals Limited³
Heidi Waters, MS, MBA	Centocor, Inc.²

The following speakers do not report any affiliation:
Scott A. Strong, MD
Francisco A. Sylvester, MD

All materials are included with the permission of the authors.

Oral Presenters
Those speakers who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

The following speakers do not report any affiliation:
Dahlia Awais, MD
Steven Brant, MD
Patricia Burgunder, ARNP
Michael Kappelman, MD, MPH
Lena Palmer, MD
Harjiwander Preetl Sidhu, MD
Anna Svendsen, RN
Linda Tang, MD
Akbar Waljee, MD, MSc

Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:

Keith Steward MD MBA owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.

Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.

Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

Unapproved and Investigational Uses of Drug and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities. The opinions expressed in this email case discussion are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

For questions regarding this activity, please contact

Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: elearning@imedex.com